HealthcarePress Releases

Paclitaxel Injection Market 2021 Analysis by Sales, Demand, Trends, Consumption and Growth, Forecast 2030

Share This Article

The global paclitaxel injection market was estimated at US$ 4.09 billion in 2020 and is expected to hit US$ 10.65 billion by 2030, registering a CAGR of 12.5% from 2021 to 2030, as per reports by market research and consulting organisation Precedence Research.

The report contains 150+ pages with detailed analysis. The report provides an in-depth analysis of the market size, share, emerging and current trends, future estimations, and key players.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1219

Crucial factors accountable for market growth are:

  • Growing incidence of cancer worldwide
  • Better efficiency of paclitaxel over other preparations in cancer treatment
  • Ease of availability
  • Increasing expenditure by major companies on research and development for advance of more effective paclitaxel injection
  • Launch of new products
  • Increasing per capita healthcare spending in developing regions

Competition Landscape

In the final section of the research report, Precedence Research provided the global paclitaxel injection market structure and a detailed competition landscape to provide a dashboard view of key players operating in the paclitaxel injection market along with their business strategies to report audiences. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the value chain of the market.

Some of the major players in the paclitaxel injection market include:

  • Celgene Corporation
  • Sagent Pharmaceuticals
  • Abbott Laboratories
  • Bristol Myers Squibb
  • Fresenius Kabi Oncology Ltd
  • Luye Pharma Group
  • Onco Therapies Ltd (Strides Arcolab Ltd.)
  • NOVASEP
  • Pfizer

COVID-19 Impact

The COVID-19 pandemic is having a collateral well-being effect on the availability of surgical care to millions of patients worldwide. The effect of COVID-19 on operating practice is extensive, ranging from staffing and workforce issues, procedural arrangement, risk of viral transmission intra-operatively, and the fluctuations to perioperative preparation. The affected individuals are being deprived of operating access, with undefined loss of function and hazard of adverse diagnosis as a collateral consequence of the pandemic. Individuals suffering from cancer are understood to be at greater risk of developing severe complications from the SARS CoV2 and simultaneously treatment adjournments can result in poorer oncological consequences. Proper planning is thus important to endure with cancer treatment facilities and concurrently avoid the danger of contamination to the patients and healthcare staff and not permitting community spread of the viral infection.

Market Segmentation

  • Celgene Corporation
  • Sagent Pharmaceuticals
  • Abbott Laboratories
  • Bristol Myers Squibb
  • Fresenius Kabi Oncology Ltd
  • Luye Pharma Group
  • Onco Therapies Ltd (Strides Arcolab Ltd.)
  • NOVASEP
  • Pfizer

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.
  • In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Why should you invest in this report?

If you are aiming to enter the global paclitaxel injection market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for paclitaxel injection are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1219

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Paclitaxel Injection Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Paclitaxel Injection Market

5.1. Covid-19: Paclitaxel Injection Industry Impact
5.2. Paclitaxel Injection Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Paclitaxel Injection Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Paclitaxel Injection Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Paclitaxel Injection Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing incidence of cancer worldwide
6.1.1.2. Better efficiency of paclitaxel over other preparations in cancer treatment
6.1.2. Market Restraints
6.1.2.1. High cost
6.1.3. Market Opportunities
6.1.3.1. Growing incidence of cancer worldwide
6.1.3.2. Better efficiency of paclitaxel over other preparations in cancer treatment

Chapter 7. Global Paclitaxel Injection Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Paclitaxel InjectionMarket Revenue by Market Players (2016 -2019)
7.1.1.2. Paclitaxel InjectionMarket Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Paclitaxel Injection Market, By Indication

8.1. Paclitaxel Injection Market, by Indication, 2017-2030
8.1.1. Prostate Cancer
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Non-Small Cell Lung Cancer
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. AIDS related Kaposi’s Sarcoma
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Ovarian Cancer
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Stomach Cancer
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Cervical Cancer
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Esophageal Cancer
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Testicular Cancer
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Lung Cancer
8.1.10.1. Market Revenue and Forecast (2017-2030)
8.1.11. Pancreatic Cancer
8.1.11.1. Market Revenue and Forecast (2017-2030)
8.1.12. Others
8.1.12.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Paclitaxel Injection Market, By End User

9.1. Paclitaxel Injection Market, by End User, 2017-2030
9.1.1. Cancer Research Centers
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hospital
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Other End Users
9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Paclitaxel Injection Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue Forecast by Indication (2017-2030)
10.1.2. Market Revenue Forecast by End User (2017-2030)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2017-2030)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2017-2030)
10.2. Europe
10.2.1. Market Revenue Forecast by Indication (2017-2030)
10.2.2. Market Revenue Forecast by End User (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2017-2030)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2017-2030)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Indication (2017-2030)
10.3.2. Market Revenue Forecast by End User (2017-2030)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2017-2030)
10.4. LATAM
10.4.1. Market Revenue Forecast by Indication (2017-2030)
10.4.2. Market Revenue Forecast by End User (2017-2030)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2017-2030)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2017-2030)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Indication (2017-2030)
10.5.2. Market Revenue Forecast by End User (2017-2030)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2017-2030)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2017-2030)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2017-2030)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2017-2030)

Chapter 11. Company Profiles

11.1. Celgene Corporation
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. Product Details, Specification, Indication
11.1.3. Revenue, Price, and Gross Margin (2015-2020)
11.1.4. Recent Developments and Strategies
11.2. Sagent Pharmaceuticals
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Indication
11.2.3. Revenue, Price, and Gross Margin (2015-2020)
11.2.4. Recent Developments and Strategies
11.3. Abbott Laboratories
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Indication
11.3.3. Revenue, Price, and Gross Margin (2015-2020)
11.3.4. Recent Developments and Strategies
11.4. Bristol Myers Squibb
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Indication
11.4.3. Revenue, Price, and Gross Margin (2015-2020)
11.4.4. Recent Developments and Strategies
11.5. Fresenius Kabi Oncology Ltd
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Indication
11.5.3. Revenue, Price, and Gross Margin (2015-2020)
11.5.4. Recent Developments and Strategies
11.6. Luye Pharma Group
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Indication
11.6.3. Revenue, Price, and Gross Margin (2015-2020)
11.6.4. Recent Developments and Strategies
11.7. Onco Therapies Ltd (Strides Arcolab Ltd.)
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Indication
11.7.3. Revenue, Price, and Gross Margin (2015-2020)
11.7.4. Recent Developments and Strategies
11.8. NOVASEP
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Indication
11.8.3. Revenue, Price, and Gross Margin (2015-2020)
11.8.4. Recent Developments and Strategies
11.9. Pfizer
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Indication
11.9.3. Revenue, Price, and Gross Margin (2015-2020)
11.9.4. Recent Developments and Strategies

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1219

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Follow us on LinkedIn | Twitter | Facebook

Show More

Market Stats News

Market Stats News is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services, we aim at connecting an organization’s goal with lucrative prospects globally.

Related Articles

Back to top button